C
CartiHeal
Privately-held medical device company that develops proprietary implants for the treatment of cartilage and osteochondral defects in traumatic and osteoarthritic joints
About CartiHeal
CartiHeal is an Israeli medical device company focused on developing and commercializing proprietary implants for treating cartilage and osteochondral defects in knee joints, addressing both traumatic and osteoarthritic conditions. Founded in 2009 by Nir Altschuler as a spin-out from Ben-Gurion University of the Negev, the company operates from Kfar Saba, Israel, with a sales office in New Jersey.
The company's core product is the Agili-C implant, a single-stage, off-the-shelf solution for knee cartilage and osteochondral defects. The implant is a cell-free, biocompatible, and resorbable scaffold made from aragonite, a natural form of calcium carbonate derived from coral. This porous, bi-phasic implant is designed to promote the regeneration of both the original articular cartilage and the underlying subchondral bone. The body gradually absorbs the implant over time, allowing new, healthy tissue to take its place.
CartiHeal targets a significant market, including the approximately 700,000 patients in the US who undergo cartilage repair annually. Its technology is notable for its broad indication, which includes patients with mild to moderate osteoarthritis, a demographic previously lacking effective treatment options. The business model centers on the sale of this implant to orthopedic surgeons and healthcare facilities for use in a single-step surgical procedure.
A key milestone was achieved in March 2022, when the Agili-C implant received Premarket Approval (PMA) from the U.S. Food and Drug Administration (FDA), following a 'Breakthrough Device Designation' in 2020. This approval was based on a major clinical study involving 251 patients, which demonstrated the superiority of Agili-C over the existing standard of care, such as microfracture and debridement. In January 2024, the global medical technology company Smith & Nephew completed its acquisition of CartiHeal for an initial consideration of $180 million, with potential for up to an additional $150 million based on sales performance. This acquisition integrated Agili-C into Smith & Nephew's sports medicine portfolio.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2009
- Headquarters
- Kfar Saba, Israel
- Employees
- 17
- Open positions
- None listed
- Dealroom signal
- 72.2/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices
- Sector
- Biotech & Life Sciences, Rehabilitation, Biotechnology, medical implants, Biodegradable, Regenerative Medicine, Spinout, Tech for Patients, Biotech and Pharma, DT and LS
- Business model
- Manufacturing
- Client focus
- B2C
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Nov 2023 | $330M | $330M | Smith & Nephew | ↗ |
| ACQUISITIONOther financing | Sep 2021 | $315M | — | Bioventus | — |
Growth signals
Latest recorded traffic for CartiHeal is 620 monthly website visits, down 86.2% over the last three months. CartiHeal's team declined 32% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
CartiHeal in the Kfar Saba ecosystem
The CartiHeal office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
Johnson & Johnson Innovation- AVAccess Medical Ventures
Elron
Peregrine Ventures
Series B and later2 investors entered at this stage
aMoon Fund
Bioventus
Other known investors2 additional known investors
Ben-Gurion University of the Negev
Smith & Nephew
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about CartiHeal on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See CartiHeal’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








